– USA, CA – Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to its Board of Directors.
Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward the commercial launch of its lead product, tab-cel.
“From commercialization of innovative rare oncology therapies to payer, access and reimbursement expertise, Ameet brings a wealth of experience in the cell and gene therapy space to the Atara Board,” said President and CEO, Pascal Touchon, “Ameet joins us at a critical time as we advance our first-in-kind off-the-shelf allogeneic T-cell immunotherapy and anticipate our first approvals in 2022. I am thrilled to welcome him to our Board.”
About Ameet Mallik
Ameet Mallik is CEO of Rafael Holdings, a late-stage cancer metabolism therapeutic company, and has held several leadership roles at Novartis Oncology, most recently as EVP and Head of U.S. Oncology where he was responsible for commercial and medical oncology operations. Before leading U.S. Oncology, Mr. Mallik served as the Global Head, Marketing, Value and Access as well as Head, Latin America and Canada, both for Novartis Oncology. Mr. Mallik held several commercial leadership roles earlier in his career at Novartis and Sandoz. At Sandoz, Mr. Mallik was Global Head of Biopharmaceuticals & Oncology Injectables and has previously worked as an Associate Principal at McKinsey and Company.
“Atara Biotherapeutics is an industry trailblazer for allogeneic T-cell immunotherapy and is rapidly advancing a robust pipeline,” said Mr. Mallik. “I am honored to join the Board and look forward to working with my fellow directors and the entire Atara leadership team to advance the company’s mission to transform the lives of patients with serious diseases.”
Mr. Mallik received a B.S. in Chemical Engineering and an M.S. in Biotechnology from Northwestern University and an M.B.A. from The Wharton School at the University of Pennsylvania.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune disease. With our lead program in Phase 3 clinical development, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical needs. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases or other serious diseases through the incorporation of engineered CARs or TCRs. Atara is applying this one platform to create a robust pipeline including tab-cel in Phase 3 development for Epstein-Barr virus-driven post-transplant lymphoproliferative disease and other EBV-driven diseases; ATA188, T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell immunotherapies for both solid tumors and hematologic malignancies. Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our leading-edge research, development, and manufacturing facility is based in Thousand Oaks, California.
For more information: https://www.atarabio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
